Background/aim: F-fluorodeoxyglucose (FDG) uptake measurement on positron emission tomography/computed tomography (PET/CT) is difficult in renal tumors because of the nearby renal parenchyma and urinary tract, which excrete FDG. We carefully examined the maximum standardized uptake value (SUV) on FDG-PET/CT and investigated the relationship between major glucose transporters in the kidney and clear cell renal cell carcinoma (ccRCC) progression.
Patients And Methods: Forty-five patients with ccRCC underwent FDG-PET/CT for staging and nephrectomy. Glucose transporter mRNA expression was examined in the removed kidney.
Results: SUV was increased in high-stage and high-grade tumors. Glucose transporter 1 (GLUT1) mRNA expression was higher in tumor tissues, in contrast to other glucose transporters. SUV was not correlated with GLUT1 mRNA expression. Kaplan-Meier analysis showed reduced overall and recurrence-free survival in the high SUVmax group.
Conclusion: Primary ccRCC lesions show a high SUV and GLUT1 mRNA over-expression. SUV increases with tumor upstaging and upgrading.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.21873/anticanres.15336 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pasireotide-induced hyperglycemia in Cushing's disease and Acromegaly: A clinical perspective and algorithms proposal.
Front Endocrinol (Lausanne)
December 2024
Recordati Rare Diseases, Central and Eastern Europe, Warsaw, Poland.
Pasireotide is an effective treatment for both Cushing's disease (CD) and acromegaly due to its ability to suppress adrenocorticotropic hormone and growth hormone, and to normalize insulin-like growth factor-1 levels, resulting in tumor shrinkage. However, it may also cause hyperglycemia as a side effect in some patients. The aim of this study was to review previous recommendations regarding the management of pasireotide-induced hyperglycemia in patients with CD and acromegaly and to propose efficient monitoring and treatment algorithms based on recent evidence and current guidelines for type 2 diabetes treatment.
View Article and Find Full Text PDFSodium-dependent glucose transporter 2 inhibitors: Transforming diabetic cardiomyopathy management.
World J Cardiol
December 2024
Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, Taichung 404328, Taiwan.
This article addresses the substantial findings of a study on sodium-dependent glucose transporter 2 inhibitors (SGLT2is) and their effects on myocardial function in patients with type 2 diabetes and asymptomatic heart failure. The editorial explores the broader implications of the study findings for clinical practice, thus highlighting the pivotal role of SGLT2is in improving cardiac function, reducing oxidative stress, and attenuating inflammation. It emphasizes the importance of early intervention with SGLT2is in preventing the progression of diabetic cardiomyopathy; hence, these inhibitors have the potential to transform the management of asymptomatic heart failure in patients with diabetes.
View Article and Find Full Text PDFManagement of Dysglycemia in a Pregnancy Complicated by Fanconi-Bickel Syndrome.
AACE Clin Case Rep
July 2024
Division of Endocrinology, Metabolism, and Molecular Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Background/objective: Fanconi-Bickel Syndrome (FBS) is an inherited disorder of glucose metabolism resulting from functional loss of glucose transporter 2 characterized by fasting hypoglycemia oscillating with postprandial hyperglycemia. Dysglycemia treatment strategies during FBS pregnancy have not been reported, and insulin therapy carries significant risk due to fasting hypoglycemia in FBS. We report for the first time: (1) glycemic profiles obtained via continuous glucose monitoring (CGM), (2) CGM-guided strategies for cornstarch and nutritional therapy for fasting hypoglycemia and postprandial hyperglycemia, respectively, and (3) placental glucose transporter 2 isoform expression in a pregnant individual with FBS.
View Article and Find Full Text PDFIncreasing SGLT-2 Inhibitor Prescribing Through an Integrated Case-Finding Algorithm Guided Interdisciplinary Intervention (INSPIRE).
J Am Pharm Assoc (2003)
December 2024
Endocrinologist, Senior Medical Director, Duke PHMO, Durham, NC; Professor of Medicine, Professor in Family Medicine and Community Health, Division of Endocrinology, Metabolism, Nutrition, Department of Medicine, Duke University School of Medicine, Durham, NC.
Background: Use of sodium-glucose co-transporter 2 inhibitors (SGLT-2 inhibitors) falls short of their cardiorenal protective benefits. Patient and provider-level barriers hinder the adoption of these life-saving medications. Innovative practices to provide primary care providers (PCP) with added clinical-decision support via a dedicated remote interdisciplinary diabetes rounds (IDR) team could promote SGLT-2 inhibitor selection.
View Article and Find Full Text PDFInsights into glucose-derived carbon dot synthesis via Maillard reaction: from reaction mechanism to biomedical applications.
Sci Rep
December 2024
Department of Urology, Urological Science Institute, Yonsei University College of Medicine, 50-1 Yonsei-Ro, Seodaemun-gu, Seoul, 03722, South Korea.
Carbon dots (CDs) are versatile nanomaterials that are considered ideal for application in bioimaging, drug delivery, sensing, and optoelectronics owing to their excellent photoluminescence, biocompatibility, and chemical stability features. Nitrogen doping enhances the fluorescence of CDs, alters their electronic properties, and improves their functional versatility. N-doped CDs can be synthesized via solvothermal treatment of carbon sources with nitrogen-rich precursors; however, systematic investigations of their synthesis mechanisms have been rarely reported.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!